Medical News Hubb
Advertisement
  • Home
  • News
  • Pharmaceutical
  • Medicines & Healthy Lifestyle
  • Contact us
No Result
View All Result
  • Home
  • News
  • Pharmaceutical
  • Medicines & Healthy Lifestyle
  • Contact us
No Result
View All Result
Medical News Hubb
No Result
View All Result
Home Pharmaceutical

Blueprint Medicines drug reduces mastocytosis symptoms in study

admin by admin
August 17, 2022
in Pharmaceutical



A drug made by Blueprint Medicines markedly improved symptoms of a rare immune system disorder called non-advanced systemic mastocytosis in a clinical trial that is being closely watched by investors, the company said Wednesday.

Blueprint’s stock has risen 28% to $70 this month in anticipation of the results, and the data, though inarguably positive, will lead to more discussion about the drug’s safety and efficacy as well as Blueprint’s pricing strategy for it. Called Ayvakit, it is already approved for two other indications and has a monthly wholesale cost of $35,213.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED





Source link

Previous Post

Health Bulletin 16/August/2022

Next Post

Chemsex and HIV Risk Reduction Strategies

Next Post

Chemsex and HIV Risk Reduction Strategies

Recommended

Blueprint Medicines drug reduces mastocytosis symptoms in study

August 17, 2022

Early flu season in U.S. may be peaking early, too

December 18, 2022

Don't miss it

Pharmaceutical

Mr. President, health care has a data problem

February 8, 2023
Medicines & Healthy Lifestyle

Amazon’s Virtual Health Clinic Raises Patient Privacy Issues

February 8, 2023
Medicines & Healthy Lifestyle

Know The Health Benefits Of Irish Sea Moss

February 8, 2023
News

Sharp Cutoff at Age 70

February 8, 2023
Pharmaceutical

Medical Bulletin 8/February/2023

February 8, 2023
Pharmaceutical

Biden to call for expanding caps on insulin prices

February 7, 2023

© 2022 Medical News Hubb All rights reserved.

Use of these names, logos, and brands does not imply endorsement unless specified. By using this site, you agree to the Privacy Policy and Terms & Conditions.

Navigate Site

  • Home
  • News
  • Pharmaceutical
  • Medicines & Healthy Lifestyle
  • Contact us

Newsletter Sign Up

No Result
View All Result
  • Home
  • News
  • Pharmaceutical
  • Medicines & Healthy Lifestyle
  • Contact us

© 2022 Medical News Hubb All rights reserved.